Merus touts bispecific antibody efficacy data with a later data cut-off in uncommon NRG1+ cancers: #ESMO23

Reynald Castañeda

Deputy Editor

MADRID — Merus unveiled further efficacy data on Monday for its bispecific antibody zenocutuzumab, which further demonstrates “robust and durable” response in patients with NRG1+ non …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merus touts bispecific antibody efficacy data with a later data cut-off in uncommon NRG1+ cancers: #ESMO23

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Former FDA chief calls job cuts ‘haphazard, poorly thought-out’

NIH payment cuts are 'reasoned and rational,' government says

Novo looks to recoup $830M from hypertension drug partner, claiming fraud

After research pivot, Biogen beefs up pipeline with Stoke's late-stage Dravet candidate

Arcus touts early kidney cancer data as Gilead declines option

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Merus touts bis­pe­cif­ic an­ti­body ef­fi­ca­cy da­ta with a lat­er da­ta cut-off in un­com­mon NRG1+ can­cers: #ES­MO23

Deputy Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Merus touts bispecific antibody efficacy data with a later data cut-off in uncommon NRG1+ cancers: #ESMO23